carrie bourdow chief operating officer of trvn presented at our th annual
healthcare conference during the presentation management focused on its lead
product olinvo oliceridine recallolinvo is a late stage asset being developed
for the management of moderate to severe acute pain the next major catalysts
that management highlighted were olinvo upcoming advisory coittee meeting
likely to be in q and olinvo pdufa date on november   management
reiterated its belief that olinvo will be differentiated from other opioids due to its more
rapid onset of action and improved safety profile management also noted a potential
average cost per day in the   range and expects to focus on “early adopter”
hospitals ie users of products such as ofirmev exparel early in launch on the
pipeline management continues to expect additional data from its dosing study for
trv being developed for the treatment of migraine in the coming months